For instance, PLS3 can enhance p38 MAPK‐mediated apoptosis induced by paclitaxel,31 and PDK2 overexpression is closely linked with cisplatin resistance in lung adenocarcinoma, as well as paclitaxel‐resistant lung cancer cells, as combining paclitaxel with a specific PDK2 inhibitor had a synergistic inhibitory effect on paclitaxel‐resistant lung cancer cells.32, 33. Here, PLS3 is linked to lung carcinoma.